Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
2.110
-0.660 (-23.83%)
At close: Jun 17, 2026, 4:00 PM EDT
2.330
+0.220 (10.43%)
After-hours: Jun 17, 2026, 7:58 PM EDT

Spero Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
122131567891621
Market Cap Growth
-20.25%133.76%-27.82%-14.15%-85.38%9.38%
Enterprise Value
68.5294.087.647.12-11.71529.91
Last Close Price
2.112.331.031.471.7316.01
PE Ratio
8.0915.53-3.42--
Forward PE
3.154.88----
PS Ratio
2.001.971.170.751.7033.99
PB Ratio
2.312.231.220.731.207.03
EV/Sales Ratio
1.121.410.160.07-0.2229.03
EV/EBITDA Ratio
-14.90-0.330.28-
EV/EBIT Ratio
4.8314.90-0.330.28-
EV/FCF Ratio
9.46---1.51-
Debt / Equity Ratio
0.010.020.060.040.070.62
Debt / EBITDA Ratio
0.180.46-0.25--
Debt / FCF Ratio
0.34-----
Net Debt / Equity Ratio
-1.01-0.63-1.05-0.66-1.35-1.03
Net Debt / EBITDA Ratio
-3.97-5.920.66-3.242.481.04
Net Debt / FCF Ratio
-7.412.962.072.1513.251.41
Asset Turnover
0.960.740.330.680.360.11
Quick Ratio
10.237.402.154.675.097.98
Current Ratio
10.507.592.193.535.258.46
Return on Equity (ROE)
-12.87%17.30%-89.62%30.63%-56.53%-81.47%
Return on Assets (ROA)
21.47%7.24%-50.09%15.42%-28.52%-54.22%
Return on Invested Capital (ROIC)
105.97%23.64%-112.22%39.00%-212.53%-555.51%
Return on Capital Employed (ROCE)
23.78%10.39%-70.98%17.30%-33.02%-60.36%
Earnings Yield
12.47%6.44%-29.25%--
Buyback Yield / Dilution
-9.20%-9.26%-1.98%-40.98%-21.65%-38.01%
Total Shareholder Return
-9.20%-9.26%-1.98%-40.98%-21.65%-38.01%
SEC Filings: 10-K · 10-Q